Ashland Inc. ASH
72.40 USD -1.72 (-2.32%)
Regular-session close
72.40 0.00 0.00%
After hours · Nov 20, 6:02 PM ET
72.30 Day range 74.58
48.19 52-week range 79.50
- YTD
- +23.40%
- 1 year
- +50.27%
News
globenewswire.com Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH) Primary analysis from a potentially pivotal trial of Ordspono ® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development…
businesswire.com Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026 PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026.
globenewswire.com Adaptive Biotechnologies Highlights clonoSEQ's Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026 Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies Approximately…
defenseworld.net Reviewing Perimeter Solutions (NYSE:PRM) & Ashland (NYSE:ASH) Perimeter Solutions (NYSE: PRM - Get Free Report) and Ashland (NYSE: ASH - Get Free Report) are both mid-cap materials companies, but which is the superior stock? We will contrast the two companies…
gurufocus.com Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional Estrella Immunopharma, Inc. (NASDAQ: ESLA) (âEstrellaâ or the âCompanyâ), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS
businesswire.com Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell…benzinga.com Wells Fargo Maintains Equal-Weight on Ashland, Raises Price Target to $80 Wells Fargo analyst Abigail Eberts maintains Ashland (NYSE:ASH) with a Equal-Weight and raises the price target from $75 to $80.
benzinga.com JP Morgan Maintains Overweight on Ashland, Raises Price Target to $82 JP Morgan analyst Jeffrey Zekauskas maintains Ashland (NYSE:ASH) with a Overweight and raises the price target from $80 to $82.
benzinga.com Ashland Q4 2026 Earnings Call Transcript Ashland (NYSE:ASH) reported fourth-quarter financial results on Wednesday. The transcript from the company’s fourth-quarter earnings call has been provided below.This transcript is brought to you by…
